कृपया अन्य खोज का प्रयास करें
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Ramon Martin Chavez Marquez | 57 | 2020 | Independent Chair of the Board |
Robert J. Lollini | 70 | 2014 | Member of Business Advisory Panel |
Terry-Ann Burrell | 47 | 2020 | Independent Director |
Joseph P. Miletich | 72 | 2021 | Chairman of Therapeutics Advisory Board |
Anne Carpenter | - | 2014 | Member of Scientific and Technical Advisory Board |
Kirk R. Thomas | - | 2014 | Member of Scientific & Technical Advisory Board |
H. Perry Fell | 67 | 2014 | Member of Business Advisory Panel |
Zavain Dar | 35 | 2016 | Independent Director |
Dean Y. Li | 61 | 2013 | Co-Founder & Independent Director |
Zachary S. Bogue | 49 | 2018 | Independent Director |
Robert M. Hershberg | 62 | 2020 | Independent Director |
Blake C. Borgeson | 42 | 2013 | Co-Founder & Director |
Christopher C. Gibson | 41 | 2013 | Co-Founder, CEO & Director |
Najat Khan | - | 2024 | Chief R&D Officer, Chief Commercial Officer and Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है